{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:55Z","timestamp":1790821555351,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.msard.2025.106625","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T21:51:11Z","timestamp":1753048271000},"page":"106625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4804-235X","authenticated-orcid":false,"given":"Matthijs M","family":"Versteegh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Huygens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106625_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106257","article-title":"Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: a systemic review and meta-analysis","volume":"94","author":"Baig","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106625_bib0026","article-title":"Estimation of transition probabilities from a large cohort (>6000) of Australians living with Multiple sclerosis (MS) for changing disability severity classifications, MS phenotype, and disease-modifying therapy classifications","author":"Campbell","year":"2024","journal-title":"Pharmaco Econ."},{"key":"10.1016\/j.msard.2025.106625_bib0020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40120-024-00589-7","article-title":"Holistic, long-term management of people with relapsing multiple sclerosis with Cladribine tablets: expert opinion from France","volume":"13","author":"Ciron","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106625_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105100","article-title":"Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model","volume":"80","author":"Corsten","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106625_bib0014","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","article-title":"Narrative review on the use of cladribine tablets as exit therapy for stable elderly patients with Multiple sclerosis","volume":"13","author":"de Seze","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106625_bib0016","article-title":"European experience of cladribine tablets in elderly patients with multiple sclerosis: could it be the last treatment?","volume":"11","author":"de Seze","year":"2025","journal-title":"Mult. Scler. J. \u2013 Exp. Transl. Clin"},{"key":"10.1016\/j.msard.2025.106625_bib0019","doi-asserted-by":"crossref","first-page":"e1187","DOI":"10.1212\/NXI.0000000000001187","article-title":"Early reduction of MRI activity during 6 months of treatment with cladribine tablets for highly active relapsing multiple sclerosis","volume":"9","author":"de Stefano","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106625_bib0011","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2025.106625_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.671","article-title":"Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation","volume":"7","author":"Gonz\u00e1lez-Suarez","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.msard.2025.106625_bib0021","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jval.2021.05.020","article-title":"Modeling the cost-utility of treatment sequences for multiple sclerosis","volume":"24","author":"Huygens","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2025.106625_bib0027","doi-asserted-by":"crossref","unstructured":"Marcel F. Jonker, Bas Donkers, Lucas M.A. Goossens, Renske J. Hoefman, Lea J. Jabbarian, Esther W. de Bekker-Grob, Matthijs M. Versteegh, Gerard Harty, Schiffon L. Wong, Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options, 2020. https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/0272989X19897944.","DOI":"10.1177\/0272989X19897944"},{"key":"10.1016\/j.msard.2025.106625_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1197212","article-title":"Impact of aging on treatment considerations for multiple sclerosis patients","volume":"14","author":"Macaron","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106625_bib0007","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/13524585241250199","article-title":"Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis","volume":"30","author":"Meng","year":"2024","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.msard.2025.106625_bib0002","unstructured":"Nederlandse Vereniging Neurologie. Richtlijn multiple sclerose (MS). https:\/\/richtlijnendatabase.nl\/richtlijn\/multiple_sclerose_ms\/startpagina_addendum_multiple_sclerose.html (2023)."},{"key":"10.1016\/j.msard.2025.106625_bib0006","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/13524585241245296","article-title":"Extended interval dosing with ocrelizumab in multiple sclerosis","volume":"30","author":"Novak","year":"2024","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.msard.2025.106625_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004073","article-title":"UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model","volume":"4","author":"Palace","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.msard.2025.106625_bib0009","article-title":"Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience","volume":"14","author":"Perncezky","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.msard.2025.106625_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.10.006","article-title":"Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis","volume":"6","author":"Protopapa","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.msard.2025.106625_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing \u2013 similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106625_bib0010","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106625_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106145","article-title":"De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: a pilot study","volume":"92","author":"Sacco","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106625_bib0004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.msard.2025.106625_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241233858","article-title":"Cladribine tablets after treatment with natalizumab (CLADRINA) \u2013 rationale and design","volume":"17","author":"Sguigna","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106625_bib0018","unstructured":"Sguigna, P. et al. Two-year findings on the safety and efficacy of cladribine tablets after treatment with Natalizumab (CLADRINA Trial). in (2025)."},{"key":"10.1016\/j.msard.2025.106625_bib0024","article-title":"Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model","volume":"9","author":"Smets","year":"2023","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106625_bib0025","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/13524585241258692","article-title":"Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model","volume":"30","author":"Smets","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106625_bib0012","first-page":"392","article-title":"Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)","volume":"95","author":"Toorop","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106625_bib0023","article-title":"Effectiveness and cost-Effectiveness of 360 disease-modifying treatment escalation sequences in multiple sclerosis","volume":"0","author":"Versteegh","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2025.106625_bib0003","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00415-024-12273-9","article-title":"Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials","volume":"271","author":"Zid","year":"2024","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:21:43Z","timestamp":1780039303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["S2211034825003670"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106625","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106625"}}